Clinical Challenges in the Biopsychosocial Interface

Description

Psychosomatic medicine may be considered to be one of the leading approaches to treating comorbid disorders and conditions. The chapters of this volume are written by experts in the field and present the newest developments in psychosomatic medicine, from basic science to clinical approaches and novel treatments. Discussed are communications with patients suffering from serious illness, basic science and management of fibromyalgia and chronic fatigue. Further psychiatric symptomatology in Huntington's disease and its management as well as coping with losses, grief and mourning in prostate cancer are reviewed. Psychocutaneous diseases, the role of telomeres in stress and mental illness, dimensional psychopharmacology in somatizing patients and many other clinically important areas are also covered. Papers in this publication offer new information on the advances of contemporary psychosomatic medicine in variety of areas previously not sufficiently covered and are of valuable reading for psychiatrists, psychologists, internists, oncologists and primary care specialists.

Informations

• Publié par: S. Karger AG
• Date de parution: 24 mars 2015
• Nombre de lectures: 0
• EAN13: 9783318029673
• Langue: English
• Poids de l'ouvrage: 1 Mo

Extrait

Clinical Challenges in the Biopsychosocial Interface
Advances in Psychosomatic Medicine
Vol. 34
Series Editor
T.N. Wise Falls Church, Va.
Editors
R. Balon Detroit, Mich.
G.A. Fava Bologna
I. Fukunishi Tokyo
M.B. Rosenthal Cleveland, Ohio
Clinical Challenges in the Biopsychosocial Interface
Update on Psychosomatics for the 21st Century
Volume Editors
R. Balon Detroit, Mich.
T.N. Wise Falls Church, Va.
9 Figures, 16 tables, 2015
Advances in Psychosomatic Medicine
Founded 1960 by F. Deutsch (Cambridge, Mass.) A. Jores (Hamburg) B. Stockvis (Leiden)
Continued 1972-1982 by F. Reichsman (Brooklyn, N.Y.)
Library of Congress Cataloging-in-Publication Data
Clinical challenges in the biopsychosocial interface: update on psychosomatics for the 21st century / volume editors, R. Balon, T.N. Wise.
p. ; cm. –– (Advances in psychosomatic medicine, ISSN 0065-3268 ; vol. 34)
Includes bibliographical references and indexes.
ISBN 978-3-318-02966-6 (hard cover: alk. paper) –– ISBN 978-3-318-02967-3 (electronic version)
I. Balon, Richard, editor. II. Wise, Thomas N., editor. III. Series: Advances in psychosomatic medicine ; v. 34. 0065-3268
[DNLM: 1. Psychosomatic Medicine––methods. W1 AD81 v.34 2015 / WM 90]
RC49
616.08––dc23
2015002067
Bibliographic Indices. This publication is listed in bibliographic services, including Current Contents ® and Index Medicus.
Disclaimer. The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the book is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Drug Dosage. The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
© Copyright 2015 by S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland)
www.karger.com
Printed in Germany on acid-free and non-aging paper (ISO 9706) by Kraft Druck, Ettlingen
ISSN 0065-3268
e-ISSN 1622-2855
ISBN 978-3-318-02966-6
e-ISBN 978-3-318-02967-3
Contents
Preface
Balon, R. (Detroit, Mich.); Wise, T.N. (Falls Church, Va.)

Psychosomatic Medicine in the 21st Century: Understanding Mechanisms and Barriers to Utilization
Wise, T.N. (Falls Church, Va.); Balon, R. (Detroit, Mich.)
Communication with Patients Suffering from Serious Physical Illness
Grassi, L.; Caruso, R. (Ferrara); Costantini, A. (Rome)
Dimensional Psychopharmacology in Somatising Patients
Biondi, M.; Pasquini, M. (Rome)
Forensic Issues in Medical Evaluation: Competency and End-of-Life Issues
Soliman, S. (Northfield, Ohio); Hall, R.C.W. (Orlando, Fla.)
Then and Now ... HIV Consultation Psychiatry Update
Goforth, H.W. (Cleveland, Ohio); Bader, M. (Chapel Hill, N.C.); Fernandez, F. (Harlington, Tex.)
Fibromyalgia and Chronic Fatigue: The Underlying Biology and Related Theoretical Issues
Romano, G.F. (London); Tomassi, S. (Verona); Russell, A.; Mondelli, V.; Pariante, C.M. (London)
Fibromyalgia and Chronic Fatigue Syndrome: Management Issues
Bourke, J. (London)
Telomeres, Early-Life Stress and Mental Illness
Ridout, S.J.; Ridout, K.K.; Kao, H.-T.; Carpenter, L.L.; Philip, N.S.; Tyrka, A.R.; Price, L.H. (Providence, R.I.)
Coping with Losses, Grief, and Mourning in Prostate Cancer
Wittmann, D. (Ann Arbor, Mich.)
Psychodermatology
Brown, G.E. (Tucson, Ariz./San Francisco, Calif.); Malakouti, M. (San Francisco, Calif./North Chicago, Ill.); Sorenson, E. (San Francisco, Calif./Los Angeles, Calif.); Gupta, R. (Berywn, Ill.); Koo, J.Y.M. (San Francisco, Calif.)
Huntington's Disease: Looking Beyond the Movement Disorder
Morreale, M.K. (Detroit, Mich.)
Joint Hypermobility, Anxiety and Psychosomatics: Two and a Half Decades of Progress Toward a New Phenotype
Bulbena, A.; Pailhez, G. (Barcelona); Bulbena-Cabré, A. (Barcelona/New York, N.Y.); Mallorquí-Bagué, N. (Barcelona); Baeza-Velasco, C. (Paris)
Author Index
Subject Index
Preface
Medicine has always been a changing field in terms of explanations of disease states, the appearance of new disorders, and therapeutic interventions. Psychiatry and psychosomatic medicine are in a dramatic state of change if one takes a decades-long perspective. Only a century ago, therapeutic options were almost nonexistent for the major psychoses. Within two decades, convulsive therapies offered an option for psychotic depressions. A few decades later, the advent of neuroleptics offered hope to those with schizophrenia who previously languished in isolated hospital wards. More recently, newer antidepressants have minimized side effects and allowed primary care physicians to effectively treat uncomplicated mood and anxiety disorders.
However, as time moves forward, problems both persist in the limited access of patients with psychiatric disorders to care and arise with new challenges, such as the reduced length of stay demanded by third-party payors and the ever-increasing prices of both new and old treatments. Another challenge is the high comorbidity of chronic mental illnesses and various chronic physical illnesses, such as diabetes mellitus, obesity, and cardiovascular disease, which significantly contributes to the shortened lifespan of people with chronic mental illness. Finally, the stigmas of mental illness, substance abuse, and some physical illnesses present yet another challenge, as they constitute yet another barrier in access to health care, especially in patients with multiple stigmatizing conditions.
The rise of population medicine, with special attention to preventive measures and to the importance of treating psychiatric disorders, substance abuse, and comorbid illnesses, may offer better treatments and increased access to care.
Psychosomatic medicine is considered to be one of the leading approaches to treating comorbid disorders and conditions, such as distress in the patient with cancer, demoralization and depression in the dermatological patient, or anxiety in the patient awaiting surgery. This volume addresses new, psychosomatic views on such conditions and approaches. It crisscrosses psychosomatic medicine, from basic sciences to clinical medicine, and discusses areas previously covered rarely, if at all, such as telomeres and mental illness, communication with seriously ill patients, fibromyalgia, psychiatric symptomatology in Huntington's disease, grieving in prostate cancer patients, and dimensional psychopharmacology. We hope that this volume offers new ideas and increased recognition of the advances of contemporary psychosomatic medicine.
Richard Balon , MD Thomas N. Wise , MD
Balon R, Wise TN (eds): Clinical Challenges in the Biopsychosocial Interface. Update on Psychosomatics for the 21st Century. Adv Psychosom Med. Basel, Karger, 2015, vol 34, pp 1-9 (DOI: 10.1159/000369043)
______________________
Psychosomatic Medicine in the 21st Century: Understanding Mechanisms and Barriers to Utilization
Thomas N. Wise a Richard Balon b
a Departments of Psychiatry at Inova Fairfax Hospital, Johns Hopkins University, George Washington University, and Virginia Commonwealth University, Falls Church, Va., and b Departments of Psychiatry and Behavioral Neurosciences and Anesthesiology, Wayne State University, Detroit, Mich., USA
______________________
Abstract
The psychosomatic approach arose in antiquity as mankind looked for explanations for illness and death. With the rise of modern medicine, the links between emotions and medical conditions, such as cardiac disease and diabetes, were described by astute clinical observers, but the mechanisms for these conditions were based on correlation from observations rather than on experimental design. Psychoanalytic theory was often utilized to explain many common diseases. For example, peptic ulcer disease was blamed upon anger and stress, but scientific methodology discovered Helicobacter pylori to be the significant causal factor of this disease and resulted in the development of more effective treatments. Nevertheless emotional factors are still linked to disease states and morbidity; for example, depression is a risk factor for mortality following myocardial infarction. Advances in neuroscience demonstrate that the reduction of telomere length by anxiety and stress leads to more rapid aging and potential disease vulnerability. Thus, neuroscientific probes may allow for the eluci